Amryt Pharma (Amryt Pharma) Long-Term Debt : $208.6 Mil (As of Sep. 2022)

View and export this data going back to 2019. Start your Free Trial

What is Amryt Pharma Long-Term Debt?

Amryt Pharma's Long-Term Debt for the quarter that ended in Sep. 2022 was $208.6 Mil.

Amryt Pharma's quarterly Long-Term Debt increased from Mar. 2022 ($205.5 Mil) to Jun. 2022 ($207.1 Mil) and increased from Jun. 2022 ($207.1 Mil) to Sep. 2022 ($208.6 Mil).

Amryt Pharma's annual Long-Term Debt increased from Dec. 2019 ($178.5 Mil) to Dec. 2020 ($188.4 Mil) and increased from Dec. 2020 ($188.4 Mil) to Dec. 2021 ($199.2 Mil).

Amryt Pharma Long-Term Debt Historical Data

The historical data trend for Amryt Pharma's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amryt Pharma Long-Term Debt Chart

Amryt Pharma Annual Data

Trend

Mar12

Mar13

Mar14

Mar15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Long-Term Debt

Get a 7-Day Free Trial

12.72

19.01

178.47

188.39

199.18

Amryt Pharma Quarterly Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Long-Term Debt	Get a 7-Day Free Trial															196.39	199.18	205.51	207.06	208.60

Amryt Pharma (NAS:AMYT) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Amryt Pharma Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Amryt Pharma's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Amryt Pharma (Amryt Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amryt Pharma PLC (NAS:AMYT) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

196 High Road, Dept 920A, Wood Green, London, GBR, N22 8HH

Website

http://www.amrytpharma.com

Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).